New drug senaparib tested in Real-World ovarian cancer study

NCT ID NCT07586449

Not yet recruiting Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is to understand how senaparib is actually used and tolerated by patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: senaparib (a PARP inhibitor drug)
What this could lead to: If successful, this study could show how well senaparib works in everyday practice for ovarian cancer, potentially guiding better treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also not yet recruiting, so outcomes are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER (OVCA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.